Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines

Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received European Union (EU) -Approved COVID-19 Vaccines

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04954651

Enrollment

1000

Registered

2021-07-08

Start date

2021-07-07

Completion date

2022-03-28

Last updated

2022-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV2 Infection, Vaccine Reaction

Keywords

sars-cov2, vaccine, age

Brief summary

Patients who voluntarily visit vaccination centers in Greece against COVID-19 are recruited and their immunization levels against Sars-Cov2 are assesed by measurement of the levels of serum antibodies against Sars-cov-2 before vaccination and in time intervals up to 6-9 months post-vaccination (indicatively 0-1-3-6-9 months post-vaccination).

Interventions

BIOLOGICALApproved vaccines against Sars-Cov2

Subjects who voluntarily are vaccinated against Sars-Cov-2 with any of the approved vaccines by EU

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Subjects who voluntarily receive COVID-19 vaccination

Exclusion criteria

* Patients who do not complete their vaccination * Patients who do not provide info on their health status

Design outcomes

Primary

Measure	Time frame
Antibody titer against Sars-Cov2	0-9 months

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026